On November 6, 2024, Craig Hopkinson, Executive Vice President of Research & Development and Chief Medical Officer at Alkermes PLC (ALKS, Financial), sold 10,471 shares of the company. Following this transaction, the insider now owns 99,238 shares of Alkermes PLC. Details of the sale can be found in the SEC Filing.
Alkermes PLC is a biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for the treatment of central nervous system (CNS) diseases such as schizophrenia, depression, addiction and multiple sclerosis.
Over the past year, Craig Hopkinson has sold a total of 10,471 shares and has not made any purchases of the company's stock. In the same period, there have been four insider sells and no insider buys at Alkermes PLC.
Shares of Alkermes PLC were trading at $29.53 on the day of the transaction. The company has a market cap of approximately $4.74 billion. The price-earnings ratio of Alkermes PLC is 15.02, which is lower than the industry median of 23.99 and also below the company's historical median.
According to the GF Value, the intrinsic value estimate for Alkermes PLC is $28.48 per share, making the stock Fairly Valued with a price-to-GF-Value ratio of 1.04.
The GF Value is calculated based on historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor which considers past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
